Overview

A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma

Status:
Active, not recruiting

Trial end date:
2023-01-30

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy and safety of Tislelizumab as first line treatment in combination with chemotherapy in participants with advanced unresectable/metastatic ESCC.

Phase:

Phase 3

Details

Lead Sponsor:

BeiGene

Treatments:

Capecitabine
Cisplatin
Fluorouracil
Oxaliplatin
Paclitaxel